PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease. Three PDA001 dose levels were evaluated.

Key facts

Study ID

NCT01155362

Run by

Celularity Incorporated

People needed

50

Starts

2010-08-01

Expected to finish

2014-04-01

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females ages 18-75 years
• Understand and voluntarily sign an informed consent
• Able to adhere to the study visit schedule and other protocol requirements
• Minimum weight of 50 kg
• A female of childbearing potential (FCBP)† must have a negative urine pregnancy test at screening (Visit 1) and immediately prior to all doses of IP. In addition, sexually active FCBP must agree to use two of the adequate forms of contraception methods for the duration of the study and the follow-up period. A FCBP must agree to have pregnancy tests at least every 4 weeks during the study. Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP for the duration of the study and the follow-up period.
• Subject must have inflammatory CD 6 months prior to treatment and have confirmation of ongoing disease activity by colonoscopy or (other method) at screening
• Subject must have a CDAI score > 220 and < 450 as assessed between Visit 1 and Visit 2
• The Subject must have failed, i.e., had an inadequate response or lost response (recurrence of symptoms) to an agent, or documented intolerance to an agent at any time

You may not qualify if…

• Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
• Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
• A female of childbearing potential is a sexually mature woman who:
• has not undergone a hysterectomy or bilateral oophorectomy
• has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Where it is running

• Cedars Sinai Medical Center — Los Angeles, California, United States
• University of California, Irvine — Orange, California, United States
• Yale School of Medicine Digestive Diseases — New Haven, Connecticut, United States
• University of Florida — Gainesville, Florida, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• Mt Sinai Hospital — New York, New York, United States
• Rochester General Hospital — Rochester, New York, United States
• Stony Brook University — Stony Brook, New York, United States
• Case Western Reserve University — Cleveland, Ohio, United States
• Vanderbilt University — Nashville, Tennessee, United States
• Baylor College of Medicine — Houston, Texas, United States
• McGuire VA Medical Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.